Northwest Biotherapeutics Gains Positive Outlook with Innovative Therapy

First Berlin Equity Research initiated coverage on Northwest Biotherapeutics Inc., a late-stage oncology company. The firm recommends a "Buy" rating with a price target of USD 1.00, highlighting significant potential upside. The focus lies on DCVax-L, a dendritic cell immunotherapy for glioblastoma (GBM), a severe brain cancer.

The phase 3 study of DCVax-L showed promising results, with improved overall survival for newly diagnosed and recurrent GBM patients. Survival extended to 19.3 months and 13.2 months, respectively, surpassing traditional benchmarks.

A Marketing Authorisation Application was submitted to the UK MHRA in 2023. A regulatory decision is anticipated in 2026, potentially leading to market launch in the UK in 2027, followed by international expansion post-2029 after further regulatory approvals.